Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/4439
A61K-009/48
A61K-033/10
출원번호
US-0287888
(2005-11-28)
등록번호
US-8815916
(2014-08-26)
발명자
/ 주소
Olmstead, Kay
Hall, Warren
Proehl, Gerald T.
출원인 / 주소
Santarus, Inc.
대리인 / 주소
Novak Druce Connolly Bove + Quigg LLP
인용정보
피인용 횟수 :
0인용 특허 :
138
초록▼
The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other im
The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.
대표청구항▼
1. A pharmaceutical formulation in a single capsule dosage form consisting of: (a) about 10 mgs to about 100 mgs of at least one micronized bicyclic aryl-imidazole acid-labile proton pump inhibitor;(b) at least one antacid, wherein the antacid comprises about 400 mgs to about 1400 mgs of sodium bica
1. A pharmaceutical formulation in a single capsule dosage form consisting of: (a) about 10 mgs to about 100 mgs of at least one micronized bicyclic aryl-imidazole acid-labile proton pump inhibitor;(b) at least one antacid, wherein the antacid comprises about 400 mgs to about 1400 mgs of sodium bicarbonate;(c) about 2 wt-% to about 5 wt-% of a disintegrant; and(d) about 0.5 wt-% to about 3 wt-% of Magnesium Stearate wherein upon oral administration of the capsule to a fasted human subject, a Tmax of the proton pump inhibitor is obtained within 60 minutes after administration on day 1; and an initial serum concentration of the proton pump inhibitor is greater than 300 ng/ml within 45 minutes after administration. 2. The pharmaceutical formulation according to claim 1, wherein the proton pump inhibitor is omeprazole, esomeprazole or lansoprazole, or a salt thereof. 3. The pharmaceutical formulation according to claim 1, wherein the antacid further comprises potassium bicarbonate, sodium carbonate, calcium carbonate, magnesium oxide, magnesium hydroxide, magnesium carbonate, aluminum hydroxide, or mixtures thereof; and the total amount of antacid present in the capsule is about 10 mEq. 4. The pharmaceutical formulation according to claim 1, wherein the sodium bicarbonate is present in an amount of at least 800 mgs. 5. The pharmaceutical formulation according to claim 1, wherein the disintegrant is croscarmellose sodium and is present in an amount of about 3 wt-%. 6. The pharmaceutical formulation according to claim 1, wherein the disintegrant is present in an amount of about 3 wt-% to about 5 wt-%. 7. The pharmaceutical formulation of claim 1, wherein Tmax of the proton pump inhibitor on day 7 is obtained within 60 minutes after oral administration of the capsule to the subject. 8. The pharmaceutical formulation according to claim 1, wherein the average Cmax of the proton pump inhibiting agent is less than 1250 ng/ml after oral administration of the capsule to the subject. 9. A pharmaceutical formulation in a single capsule oral dosage form consisting of: (a) micronized omeprazole or a salt thereof in an amount of about 20 mgs or about 40 mgs;(b) about 800 mgs to about 1400 mgs of sodium bicarbonate (NaHCO3);(c) about 2 wt-% to about 8 wt-% of a disintegrant; and(d) about 0.5 wt-% to about 3 wt-% of Magnesium Stearate. 10. The pharmaceutical composition of claim 9, wherein: (a) the NaHCO3 is present in an amount of between 1000 mgs and 1300 mgs; and(b) the disintegrant is croscarmellose sodium and is present in an amount of about 3 wt-% to about 5 wt-%; wherein upon oral administration of the capsule to a fasted human subject, a Tmax of the proton pump inhibitor is obtained within 60 minutes after administration on day 1. 11. A method of inhibiting a gastric acid related gastrointestinal disorder in a subject comprising administering one or more capsules of a single capsule oral dosage form to a human subject in need thereof, the single capsule oral dosage form consisting of: (a) about 10 mgs to about 100 mgs of at least one micronized bicyclic aryl-imidazole acid-labile proton pump inhibitor;(b) an antacid, wherein the antacid comprises about 400 mgs to about 1400 mgs of sodium bicarbonate (NaHCO3);(c) about 2 wt-% to about 5 wt-% of a disintegrant; and(d) about 0.5 wt-% to about 3 wt-% of Magnesium Stearate wherein upon oral administration of the capsule to a fasted human subject, a Tmax of the proton pump inhibitor is obtained within 60 minutes after administration on day 1.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B., Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
Robert R. Whittle ; Frederick D. Sancilio ; Grayson Walker Stowell ; Douglas John Jenkins ; Linda B. Whittall, Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
Spickett Robert G. W. (Barcelona ESX) Vidal Jose L. F. (Barcelona ESX) Escoi Juan C. (Barcelona ESX), Antacid compositions with prolonged gastric residence time.
Alminger Tomas B. (Lindome SEX) Bergman Rolf A. (Molndal SEX) Bundgaard H. (Horsholm DKX) Lindberg Per L. (Askim SEX) Sunden Gunnel E. (Gothenburg SEX), Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-a.
Fain Gordon L. (Los Angeles CA) Lee David A. (Los Angeles CA) Lindberg Per L. (Askim CA SEX) Sachs George (Cure Wadsworth CA), Compounds including omeprazole in the treatment of glaucoma.
Briving Carin B. (Billdal SEX) Carlsson Stig A. I. (Mlnlycke SEX) Lindberg Per L. (Askim SEX) Mattsson Annie H. (Askim SEX) Nordberg Mats P. (Gothenburg SEX) Wallmark Bjrn M. G. (Mlnlycke SEX), Derivatives of benzimidazoles active as anti-ulcer agents.
Lindberg Per L. (Askim SEX) Sundn Gunnel E. (Gteborg SEX), Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B. ; Fontana Steven A., Dry blend pharmaceutical formulations.
Junggren Ulf K. (Mlnlycke SEX) Sjstrand Sven E. (Kungsbacka SEX), Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparat.
Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
Gilis Paul Marie Victor,BEX ; Smans Guido Franciscus,BEX ; Gijs Guido Jozef Maria,BEX, Immediate release pH-independent solid dosage form of cisapride.
Upson James G. (Springdale OH) Russell Carmelita M. (Cincinnati OH), Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress.
Zyck, Daniel J.; Sitler, Daniel J.; Barkalow, David G.; Knutsen, Jonathan J.; Shen, Chungsea A.; Zuehlke, Julius W.; Schnell, Philip G., Method for making coated chewing gum products including a high-intensity sweetener.
Min Dong S. (Seoul KRX) Um Kee A. (Suwon KRX) Kim Yong S. (Suwon KRX) Park Pyong W. (Seoul KRX), Method for preparing enteric-coated oral drugs containing acid-unstable compounds.
Lindberg Per,SEX ; Weidolf Lars,SEX, Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazol.
Brndstrm Arne E. (Gothenburg SEX), Method of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazole (omeprazole).
Makino Tadashi (Osaka JPX) Tabata Tetsuro (Osaka JPX) Hirai Shin-Ichiro (Kyoto JPX), Method to stabilize a pharmaceutical composition and its production.
Catrenich Carl E. (Fairfield OH) Nelson Dennis G. A. (West Chester OH), Methods and compositions of diphenyl ether phosphate esters for the treatment of gastrointestinal disorders.
Gary G. Liversidge ; W. Mark Eickhoff ; Kathleen J. Illig ; Pramod Sarpotdar ; Stephen B. Ruddy, Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract.
Brndstrm Arne E. (Gteborg SEX) Carlsson Stig A. I. (Mlnlycke SEX) Kllsson Britt I. M. (Mlndal SEX) Lindberg Per L. (Askim SEX), Novel pharmacologically active compound pyridyl methylsulfinyl benzimidazole.
Kanamaru Tsuneo,JPX ; Nakao Masafumi,JPX ; Tawada Hiroyuki,JPX ; Kamiyama Keiji,JPX, Oxazolone derivatives and their use as anti-Helicobacter pylori agent.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B. ; Fontana Steven A., Pharmaceutical unit dosage form.
Cherukuri Subraman R. ; Fuisz Richard C. ; Sanghvi Pradeepkumar P. ; Misra Tushar K. ; Sisak John R., Process for forming chewable quickly dispersing comestible unit and product therefrom.
Fuisz Richard C. ; Cherukuri Subraman R. ; Kota Suresh B. ; Stewart James L., Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom.
Larsson Magnus Erik,SEX ; Stenhede Urban Jan,SEX ; Sorensen Henrik,SEX ; von Unge Sverker Per Oskar,SEX ; Cotton Hanna Kristina,SEX, Process for synthesis of substituted sulphoxides.
Hogberg Jan-.ANG.ke,SEX ; Ioannidis Panagiotis,SEX ; Mattson Anders,SEX, Process for the preparation of a magnesium salt of a substituted sulfinyl heterocycle.
Hoerrner Robert S. (Scotch Plains NJ) Friedman Joel J. (East Brunswick NJ) Amato Joseph S. (Brooklyn NY) Liu Thomas M. (Westfield NJ) Shinkai Ichiro (Westfield NJ) Weinstock Leonard M. (Hilton Head S, Process for the preparation of antiulcer agents.
Debregeas Patrice (Versailles FRX) Leduc Grard (Malesherbes FRX), Stable compositions of gastroprotected omerprazole microgranules and process for the production thereof.
Eek Arne T. (Trosa SEX) Sjostrand Sven E. (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Eek Arne T. (Trosa SEX) Sjostrand Sven Erik (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Eek Arne T. (Trosa SEX) Sjostrand Sven Erik (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Brndstrm Arne E. (Gteborg SEX) Lindberg Per L. (Askim SEX) Starke Carl I. (Gteborg SEX) Sundn Gunnel E. (Gteborg SEX), Therapeutically active chloro substituted benzimidazole.
Brndstrm Arne E. (Gteborg SEX) Lindberg Per L. (Askim SEX) Sunden Gunnel E. (Gteborg SEX), Therapeutically active compound and a process for its preparation.
Johnstone Scott Bowen ; Jones Brad Allen ; Mellon Mark ; Rigby William Roger, Unit dose packaging system (UDPS) having a child resistant locking feature.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.